Aditya Gandhi
Known title: CAOCIK: 0001942071
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
UBS cuts Sonoco price target to $51, maintains Neutral rating. UBS has lowered its price target for Sonoco Products to $51 while keeping a Neutral rating. This move places the bank's estimate at the bottom of the current analyst range, which spans from $51 to $70. The stock is currently trading near its support level, reflecting the cautious outlook among some analysts.
Transaction History
| ATR | ▲ Buy | Grant | 2,664 | $0 | 6/15/2026 | View on chart |
| SON | ▲ Buy | Option Exercise | 962 | $0 | 2/21/2026 | View on chart |
| SON | ▼ Sell | Tax Withholding | 343 | $19K | 2/21/2026 | View on chart |
| SON | ▲ Buy | Option Exercise | 473 | $0 | 2/20/2026 | View on chart |
| SON | ▼ Sell | Tax Withholding | 169 | $10K | 2/20/2026 | View on chart |
| SON | ▲ Buy | Grant | 478 | $21K | 2/19/2026 | View on chart |
| SON | ▼ Sell | Tax Withholding | 171 | $7K | 2/19/2026 | View on chart |
| SON | ▲ Buy | Option Exercise | 374 | $0 | 2/13/2026 | View on chart |
| SON | ▼ Sell | Tax Withholding | 134 | $7K | 2/13/2026 | View on chart |
| SON | ▲ Buy | Option Exercise | 1,621 | $0 | 10/1/2025 | View on chart |
| SON | ▼ Sell | Tax Withholding | 496 | $23K | 10/1/2025 | View on chart |
| SON | ▲ Buy | Option Exercise | 472 | $0 | 2/20/2025 | View on chart |
| SON | ▼ Sell | Tax Withholding | 170 | $8K | 2/20/2025 | View on chart |
| SON | ▲ Buy | Option Exercise | 363 | $0 | 2/13/2025 | View on chart |
| SON | ▼ Sell | Tax Withholding | 131 | $6K | 2/13/2025 | View on chart |
| SON | ▲ Buy | Option Exercise | 476 | $0 | 2/10/2025 | View on chart |
| SON | ▼ Sell | Tax Withholding | 171 | $8K | 2/10/2025 | View on chart |
| SON | ▲ Buy | Option Exercise | 363 | $0 | 2/13/2024 | View on chart |
| SON | ▼ Sell | Tax Withholding | 131 | $7K | 2/13/2024 | View on chart |
| SON | ▼ Sell | Tax Withholding | 167 | $10K | 2/9/2024 | View on chart |
| SON | ▲ Buy | Option Exercise | 461 | $0 | 2/9/2024 | View on chart |
| SON | ▲ Buy | Option Exercise | 461 | $0 | 2/9/2023 | View on chart |
| SON | ▼ Sell | Tax Withholding | 167 | $10K | 2/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage
AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.